Evogene (EVGN) director details stock option grants and vesting
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Evogene Ltd. director Percy Adrian John filed an initial ownership report detailing his stock option holdings in the company. The filing lists several option awards over ordinary shares with exercise prices ranging from 1.2900 to 62.6800 and expirations between 2028 and 2035.
These options cover blocks of 250 to 2,500 underlying ordinary shares each. One grant over 2,500 underlying shares at an exercise price of 1.2900 vests in four equal quarterly installments so that it is fully vested on the one-year anniversary of the August 18, 2025 grant date. The report reflects holdings only, not new market transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
8 transactions reported
Mixed
8 txns
Insider
Percy Adrian John
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
| holding | Stock Option (right to buy ordinary shares) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy ordinary shares) — 1,000 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What does Percy Adrian John’s Form 3 for Evogene (EVGN) report?
Percy Adrian John’s Form 3 reports his existing stock option holdings in Evogene. It lists multiple option awards over ordinary shares, specifying exercise prices, expiration dates, and underlying share amounts, providing a baseline of his derivative ownership as a company director.
What stock options does Percy Adrian John hold in Evogene (EVGN)?
He holds several stock options to acquire Evogene ordinary shares. The awards cover underlying blocks from 250 to 2,500 shares each, with exercise prices between 1.2900 and 62.6800 and expirations from 2028 through 2035, all reported as directly owned.
How do Percy Adrian John’s Evogene (EVGN) options vest according to the filing?
One highlighted grant of 2,500 underlying shares vests quarterly over one year. The footnote explains it vests 25% per quarter, becoming fully vested on the one-year anniversary of the August 18, 2025 grant date, aligning vesting with continued service.
What are the expiration dates on the Evogene (EVGN) options held by Percy Adrian John?
The reported stock options expire between 2028 and 2035. Individual grants show specific expiration dates such as December 23, 2028 and August 18, 2035, defining the periods during which he can exercise these rights to buy ordinary shares.
Are Percy Adrian John’s Evogene (EVGN) options held directly or through another entity?
The filing shows Percy Adrian John’s options as directly owned. Each entry is marked with direct ownership, and there is no footnote indicating that the options are held by a separate trust, partnership, or other entity on his behalf.